PD39-02 RESULTS OF PHASE 1 CLINICAL TRIAL OF HIGH DOSES OF SELENO-L-METHIONINE (SLM) IN SEQUENTIAL COMBINATION WITH AXITINIB IN PREVIOUSLY TREATED AND RELAPSED CLEAR CELL RENAL CARCINOMA (CCRCC) PATIENTS
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.